JANUARY – FEBRUARY 2025 Shooting Cancer Highlights: Periodic focus on regulatory status of new targeted therapies in oncology
EMA January 9 – Osimertinib – NSCLC EGFR. The European Commission (EC) has approved a Type II variation extension of indication for the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as monotherapy, to include treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have EGFR […]